Captivate primary analysis of first‐line treatment with fixed‐duration ibrutinib plus venetoclax for chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll)
C. S. L Tam,J. N Allan,T Siddiqi,T. J Kipps,R Jacobs,S Opat,P. M Barr,A Tedeschi,L Trentin,R Bannerji,S Jackson,B Kuss,C Moreno,E Szafer‐Glusman,K Russell,C Zhou,J Ninomoto,J. P Dean,P Ghia,W. G Wierda
